Source disclosure: January 26, 2026
Kubota Pharmaceutical Holdings Co., Ltd. [4596.T]
TOKYO, Jan 26 (Pulse News Wire) – Kubota Pharmaceutical Holdings CO.,LTD. (4596.T) disclosed ongoing discussions with Laboratoires KÔL regarding potential collaboration on Emicstato hydrochloride, a drug candidate for Stargardt disease treatment.
Following the signing of a letter of intent, the companies are now negotiating licensing agreements for exclusive sales rights. After reviewing draft contracts, both parties agree on fundamental frameworks but require further alignment on contingency plans to ensure long-term stability. Kubota remains committed to concluding the agreement swiftly through continued negotiations.
Kubota Vision Inc., a subsidiary based in Seattle, Washington, initiated talks with Laboratoires KÔL, headquartered in Clermont-Ferrand, France, to explore commercial partnership opportunities involving Emicstato hydrochloride. The subsidiary's director, Chairman, President, and CEO, Yoshi Kubota, led the initial discussions aimed at establishing a cooperative framework for the drug’s development and distribution. Sophie Momège, founder and CEO of Laboratoires KÔL, represents the French firm in these deliberations.
AI-translated content. 🟡 Confidence: Standard See terms • Original filing